Variant report
Variant | esv3505415 |
---|---|
Chromosome Location | chr3:156092073-156093789 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:4)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:4 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr3:156089108..156092383-chr3:156093518..156096511,3 | K562 | blood: | |
2 | chr3:156089108..156092383-chr3:156093518..156096511,3 | K562 | blood: | |
3 | chr3:156090883..156092603-chr3:156093278..156096049,2 | K562 | blood: | |
4 | chr3:156090883..156092603-chr3:156093278..156096049,2 | K562 | blood: |
No data |
No data |
No data |
No data |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs116156504 | chr3:156092129-156092130 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
2 | rs141788745 | chr3:156092136-156092137 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
3 | rs4989481 | chr3:156092164-156092165 | Enhancers Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
4 | rs816545 | chr3:156092170-156092171 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
5 | rs574772056 | chr3:156092207-156092208 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
6 | rs574649039 | chr3:156092239-156092240 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
7 | rs557189918 | chr3:156092242-156092243 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
8 | rs147085921 | chr3:156092251-156092252 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
9 | rs545541054 | chr3:156092302-156092303 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs375448904 | chr3:156092405-156092406 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs528200434 | chr3:156092443-156092444 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs138595645 | chr3:156092537-156092538 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs572223131 | chr3:156092589-156092590 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs73873344 | chr3:156092590-156092591 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
15 | rs531730697 | chr3:156092632-156092633 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs190851039 | chr3:156092665-156092666 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs546092967 | chr3:156092711-156092712 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs373489945 | chr3:156092730-156092731 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs550863415 | chr3:156092856-156092857 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs562897272 | chr3:156092954-156092955 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs549861796 | chr3:156093021-156093022 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs112498224 | chr3:156093087-156093088 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
23 | rs113263517 | chr3:156093094-156093095 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs530652978 | chr3:156093170-156093171 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
25 | rs182234788 | chr3:156093186-156093187 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs138729431 | chr3:156093190-156093191 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs549391940 | chr3:156093207-156093208 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs187728485 | chr3:156093208-156093209 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
29 | rs78159212 | chr3:156093244-156093245 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs77418390 | chr3:156093257-156093258 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
31 | rs577300130 | chr3:156093273-156093274 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs575312527 | chr3:156093306-156093307 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs539597075 | chr3:156093313-156093314 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs73873345 | chr3:156093344-156093345 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
35 | rs144747665 | chr3:156093354-156093355 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs76885719 | chr3:156093389-156093390 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs192689742 | chr3:156093421-156093422 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs374270363 | chr3:156093572-156093573 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs373035761 | chr3:156093612-156093613 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs139601387 | chr3:156093619-156093620 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs71310473 | chr3:156093621-156093622 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs112566753 | chr3:156093678-156093679 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs117801816 | chr3:156093707-156093708 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs533485597 | chr3:156093754-156093755 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs188791230 | chr3:156093769-156093770 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs192931009 | chr3:156093770-156093771 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Basal cell lymphoma | 17053054 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Uveal melanoma | 21693616 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Retinoblastoma | 21504564 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Intellectual disability | 22102821 | CNVD |
Autism | 22495311 | CNVD |
Lung cancer | 18438408 | CNVD |
Squamous cell cancer | 20885788 | CNVD |
Melanoma | 18172304 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Breast cancer | 22032731 | CNVD |
Breast cancer | 16461572 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Cervical Cancer | 21857958 | CNVD |
Melanoma | 21693616 | CNVD |
Lung cancer | 21426551 | CNVD |
Cancer | 21637783 | CNVD |
Cervical cancer | 21063398 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Oral cancer | 21386901 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Cancer | 22065749 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Basal cell lymphoma | 21115979 | CNVD |
head and neck squamous cell carcinoma | 17671120 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Myelodysplastic syndrome | 21251322 | CNVD |
Blepharophimosis-ptosis-epicanthus inversus syndrome | 22067867 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Acute lymphoblastic leukemia | 21339820 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Gastrointestinal stromal cancer | 20818650 | CNVD |
Breast cancer | 16608533 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Non-small cell lung cancer | 19010865 | CNVD |
abnormal development | 18461090 | CNVD |
Prostate cancer | 18632612 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
Ovarian clear cell carcinoma | 21343371 | CNVD |
Esophageal squamous carcinoma | 17470683 | CNVD |
Cancer | 17440070 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Prostate cancer | 16547154 | CNVD |
Breast cancer | 21611746 | CNVD |
Sudden cardiac death | 19188705 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr3:156088600-156096000 | Weak transcription | Placenta | Placenta |
2 | chr3:156089600-156092600 | Enhancers | HSMMtube | muscle |
3 | chr3:156089800-156092400 | Enhancers | HUES64 Cell Line | embryonic stem cell |
4 | chr3:156090000-156092200 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
5 | chr3:156090000-156092200 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
6 | chr3:156090200-156092200 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
7 | chr3:156090200-156092400 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
8 | chr3:156090800-156094000 | Weak transcription | H1 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
9 | chr3:156090800-156100600 | Weak transcription | Fetal Muscle Leg | muscle |
10 | chr3:156091200-156092600 | Enhancers | iPS DF 6.9 Cell Line | embryonic stem cell |
11 | chr3:156091800-156092600 | Enhancers | HUES48 Cell Line | embryonic stem cell |
12 | chr3:156091800-156092800 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
13 | chr3:156091800-156095000 | Weak transcription | H9 Cell Line | embryonic stem cell |
14 | chr3:156092400-156101600 | Weak transcription | Aorta | Aorta |
15 | chr3:156092800-156093000 | Enhancers | hESC Derived CD56+ Ectoderm Cultured Cells | ES cell derived |